Summary: Many types of xenobiotic transporters have been identiˆed. They generally exhibit multispeciˆc recognition of various types of substrates, and mediate membrane permeation of therapeutic agents, thereby playing important roles in drug absorption and disposition. It has recently been proposed that protein-protein interactions involving the xenobiotic transporters may aŠect their function, localization and expression on plasma membranes. So-called adaptor proteins that directly interact with the transporters include PDZ domain-containing proteins (PSD95, Dlg and ZO1). These PDZ adaptors have multiple PDZ domains in their structure, and each PDZ domain can interact with the cytosolic region of the transporters, and so it has been hypothesized that transporters are localized within networks consisting of several transporters and adaptors. Interaction with a PDZ adaptor is essential for the cell-surface localization of at least some xenobiotic transporters, and therefore, such interaction could be required for e‹ciency andˆdelity in the vectorial transport of xenobiotics and therapeutic agents in epithelial cells. This review article summarizes recent evidence on the interactions of xenobiotic transporters with adaptor proteins, and presents a working hypothesis concerning their pharmacological signiˆcance.
Xenobiotic transporters have multiple trans-membrane domains (most have 12, but some have 6¿17) and are localized primarily on plasma membranes in pharmacokinetically important organs, including liver, kidney, small intestine and brain. Most of the xenobiotic transporters can be categorized into the ATP-binding cassette (ABC) or solute carrier (SLC) superfamily. 1, 2) Until recently, minimal information had been available on the spatial positioning of the xenobiotic transporters, i.e, how these transporters are ordered or localized (or even whether they are randomly placed) on the plasma membranes. However, there are indications that these transporters are organized into microdomains on plasma membranes. First, many types of xenobiotic transporters mediate so-called facilitated diŠusion, which requires a driving force that is usually a concentration gradient of ionic solutes across the plasma membrane. Therefore, to assure the e‹ciency of transportermediated membrane permeation, it seems reasonable that the cellular machinery that supplies the driving force to the transporters would be localized in close proximity to the corresponding transporter. Second, the xenobiotic transporters are involved in both in‰ux of nutrients into the cells and eOEux of xenobiotics, as well as metabolites, out of the cells. Therefore, they should be targeted to appropriate (basolateral or apical) membranes in epithelial cells to assureˆdelity in such vectorial transport of nutrients, xenobiotics and metabolites. Because cell-surface membranes are subjected to rapid endocytosis, followed by intracellular degradation and/or recycling of endocytosed proteins and lipids, the transporters should be stably localized on plasma membranes to mediate appropriate membrane permeation of their substrates. Therefore, machinery may be required for the xenobiotic transporters to be precisely targeted and localized on the plasma membranes. Third, xenobiotic transporters are involved in membrane permeation of numerous types of xenobiotic compounds, as well as nutrients. Such multispeciˆcity has generally been explained in terms of a wide spectrum of substrate recognition speciˆcity of each xenobiotic transporter. 3, 4) However, other factors could be required to assure such multispeciˆcity of transport systems.
Therefore, xenobiotic transporter-mediated membrane permeation may require e‹ciency,ˆdelity and multispeciˆty. The possible role of protein-protein interactions in meeting these requirements is discussed below.
Protein-protein interactions of xenobiotic transporters
So far, two domain structures are known to interact directly with the C-terminal cytosolic region of xenobiotic transporters: the PDZ (PSD95, Dlg and ZO1) and FERM (band-four point one, ezrin, radixin and moesin) domains (Fig. 1) . Kocher et al.
5)ˆr st demonstrated that the carboxylic terminus of multidrug resistance associated protein (MRP) 2 directly interacts with theˆrst PDZ domain of PDZK1. PDZK1 was identiˆed as a binding partner of another membrane protein, MAP17, which is up-regulated in renal cell carcinoma compared with normal renal parenchyma. 6) PDZK1 was also identiˆed as a protein (diphor-1) that is up-regulated under conditions of low dietary phosphate, as a protein (CLAMP) which is associated with C-terminal region of the scavenger receptor class B type I (SR-BI), and as a protein (CAP70) that interacts with the C-terminal region of cysticˆbrosis transmembrane conductance regulator protein (CFTR). [7] [8] [9] The C-terminal region of MRP2 is reported to be essential for apical localization in epithelial cells, 10, 11) but up to now, there has been no direct evidence indicating the role of PDZK1 in the function and/or localization of MRP2.
Further, it has recently been reported that PDZK1, PDZK2 (also called IKEPP and NaPi-CapII) and another PDZ domain containing protein, NHERF1 (NHE regulatory factor, also called EBP50/ SLC9A3R1), can interact with the C-terminus of various xenobiotic transporters, including organic anion transporter (OAT) 4, carnitine/organic cation transporter (OCTN) 1, OCTN2, urate transporter (URAT1), oligopeptide transporter (PEPT) 2 and organic anion transporting polypeptide (Oatp) 1a1. [12] [13] [14] [15] [16] [17] [18] [19] We have screened the interaction potential of the Cterminal region of xenobiotic transporters that belong to the SLC superfamily using yeast two-hybrid analysis and demonstrated speciˆc interactions of the four PDZ proteins (PDZK1, PDZK2, NHERF1 and NHERF2) with the C-terminal region of SLC xenobiotic transporters. 12) Most of the transporters that exhibited speciˆc interaction with either of the PDZ proteins are localized on the apical membrane in kidney and/or small intestine, implying that the transporter-PDZ interaction may be relevant to the targeting to and/or stable expression on the apical membranes. 12, 20, 21) Both PDZK1 and PDZK2 have four PDZ domains in tandem arrangements, whereas both NHERF1 and NHERF2 have two, but also possess a C-terminal ERM (ezrin, radixin and moesin) binding domain ( Fig. 1) . The PDZKs and NHERFs are thus structurally diŠerent ( Fig. 1 ), but all four PDZ proteins are sometimes recognized as one family (NHERF1 to 4) on the basis of their broad similarity, because they are more similar to one another than to other PDZ domain-containing proteins. 22) Because each PDZ domain alone can interact with the C-terminal region of the transporters, it is speculated that these PDZ proteins have multivalent interactions with various transporters, forming protein networks. The formation of protein networks was further supported by the in vitro binding potential between PDZK1 and NHERF1, and NHERF1 and NHERF1/2, although there are no data directly demonstrating that multiple transporters actually form protein complexes.
14,21) Table 1 . Consensus sequences of PDZ domain ligands at the extreme C-terminus a)
Class
Consensus Sequences The PDZ domains are generally known to interact with the so-called PDZ binding motif, usually located at the extreme C-terminus of the transporters. The PDZ domains are now categorized into at least three or four groups according to the binding motifs they can bind to ( Table 1) .
23) The class I PDZ domain is most frequently found in the C-terminus of xenobiotic transporters and binds preferntially to the amino acid sequence -[S/T]-X-[F/W] (F and W are hydrophobic and aromatic amino acids, respectively) at the C-terminus. The three other classes of PDZ domains also have preferential binding motifs ( Table 1) .
23) An atypical PDZ motif, which is diŠerent from the motifs shown in Table 1 , may also bind to PDZ domains. 24) PDZ domains can also bind to a motif localized in an internal region of proteins followed by a sharp b turn structure. 25) Thus, the PDZ domain-PDZ motif interactions may be diverse and cannot easily be predicted simply from the C-terminal amino acid sequence of each transporter.
The FERM domain in radixin was also reported to bind directly to the C-terminus of the xenobiotic transporter. Kikuchi et al. 26) observed an increase in serum concentration of conjugated bilirubin in radixin gene knockout mice and clariˆed a pivotal role of radixin in the canalicular localization of Mrp2 in the liver. Involvement of radixin as well as ezrin in the apical localization of MRP2 was also recently demonstrated in intestinal epithelial Caco-2 cells.
27) The FERM domain in radixin can directly interact with the C-terminal cytoplasmic domain of MRP2.
26) The FERM domains have a wide spectrum of binding speciˆcity, and their binding partners include various adhesion molecules and NHERF1. The a‹nity of FERM for NHERF1 was much higher (with a dissociation constant in the nM range) than that for other membranous proteins, implying that NHERF1 is an important binding partner of FERM domains. 28, 29) It is thus not clear how the FERM domain distinguishes MRP2 from other cell-surface proteins and NHERF1 in vivo. Other features of the binding of FERM domains include hydrogen bonding interaction via the backbone structure. 28, 29) Although some FERM domain-interacting motifs are known, the amino acid sequence speciˆcity may not be so restrictive as that of the PDZ binding motif. Thus, further studies are needed to clarify possible interactions of FERM domains with other transporters. The FERM domain also interacts with C-terminal domains of ERM proteins themselves, such interaction leading to an inactive form of the ERM proteins. 30) 3. Protein-protein interaction and e‹ciency of transport Double-transfectant systems have been utilized to analyze the eŠects of PDZ adaptors on xenobiotic transporters in vitro. In HEK293 cells, for example, coexpression with PDZK1 increased the apparent uptakes by OAT4, OCTN1, OCTN2, PEPT2 and URAT1 of their substrates. 12, 13, [15] [16] [17] [18] The increased uptake presumably resulted from the interaction of the transporters with PDZK1, since PDZK1 minimally aŠected the uptake activity of mutants which had minimal interaction potential with PDZK1 owing to deletion of their PDZ binding motif at the C-terminus. PDZK1 increased cell-surface expression of most of these transporters, thereby increasing transport capacity (Vmax), although it did not aŠect expression of OCTN2, but increased the Vmax of OCTN2 in HEK293 cells. 13, [16] [17] [18] Another PDZ adaptor, NHERF1, has a C-terminal PDZ binding motif that can interact with PDZK1. 14) Cotransfection of NHERF1 also increased OAT4 activity in HEK293 cells. 13) Interestingly, all of these transporters, as well as PDZK1 and NHERF1, are colocalized on apical membranes in renal proximal tubules, and can interact with one or more PDZ domains in PDZK1, 13, [16] [17] [18] supporting the existence of a protein network involving PDZK1. Stimulatory eŠects of PDZK1 and NHERF1 on OAT4 were also observed in LLC-pK1 cells, but not in BeWo cells, 31) suggesting that the transporter-PDZ interaction may be cell line-speciˆc. Thus, the regulation of transporters by the PDZ adaptors may require additional factors endogenously expressed in the host cells.
Colocalization of two or more transporters may lead to cooperative stimulation of substrate transport, providing e‹cient membrane permeation across the proximal tubules of nutrientsˆltered at the glomerulus. 32) One example of such functional coupling of two transporters is that between lactate transporters and Urat1.
33) The loss of lactate transporters in proximal tubules of c/ebpd gene knockout mice leads to increased urinary excretion of urate without any change in expression of Urat1, demonstrating functional coupling in reabsorption between lactate and urate in kidney. 33) This probably means that lactate reabsorbed via the lactate transporters is required for reabsorption of urate via Urat1.
A similar relationship was also proposed between oligopeptide transporters and Na Open bars represent uptake of GlySar or a-MDG, and closed ones represent that of an extracellular marker, mannitol. Modiˆed from Ref [37] .
(NHE). Uptake of glycylsarcosine (GlySar) by Caco-2 cells requires a H ＋ gradient as a driving force, which is supplied by NHE utilizing the Na ＋ gradient. 34) Therefore, inhibition of NHE with a speciˆc inhibitor hinders uptake of the dipeptide. The interaction potential of PDZK1 with both PEPT2 and NHE3 may imply that the PDZ adaptor acts as a scaŠold to hold the two membrane proteins in close proximity. However, there is no direct evidence yet for such a ternary complex, though double transfection of NHE3 and PEPT1 aŠects the Vmax and substrate a‹nity (1/Km) of PEPT1 in HEK293 cells heterologously transfected with these transporters. 35) Elucidation of transporter networks may thus clarify the functional coupling of membrane permeability of various nutrients, xenobiotics and metabolites. This would reveal linkages in the kinetics of various types of substances in the body, possibly allowing the discovery of biomarkers that could be used as surrogates for changes in other pharmacological/toxicological substances of interest.
PDZK1 may be involved in regulatory mechanisms for the transporters. Recently, it was demonstrated using pdzk1 gene knockout mice that the activity of Nhe3, an apically localized NHE present in kidney and intestines, is regulated by cAMP and Ca2
＋ in proximal colonic enterocytes, but such regulation was abolished in pdzk1 knockout mice, which showed minimal change in apical localization and expression of Nhe3, 36) demonstrating a fundamental role of Pdzk1 in agonist-mediated Nhe3 regulation. Possible involvement of the adaptor proteins in more speciˆc phenotypes of the transporters should be further examined.
Protein-protein interaction andˆdelity of transport
Wang et al. 19) reported down-regulation of Oatp1a1 in hepatic sinusoidal membranes in pdzk1 knockout mice, demonstrating that Pdzk1 is essential for the sinusoidal localization of Oatp1a1. A concomitant delay in the plasma disappearance of the Oatp1a1 substrate bromosulfophthalein suggests that this transporter-adaptor complex could be involved in hepatic clearance of the substrate. 19) Data obtained in our laboratory also support a fundamental role of Pdzk1 in cell-surface expression of several transporters in the small intestine (unpublished observations).
The small GTP-binding protein Rab8 was recently clariˆed to be responsible for the apical localization of several transporters including PepT1 and sodium/glucose cotransporter Sglt1 in small intestine.
37) It was reported that rab8 gene knockout is lethal at 3 weeks of age in mice (just after weaning), probably because of a marked reduction in the absorption rate of nutrients in the small intestine.
37) The uptake of both GlySar and amethyl-D-gucose (a-MDG) from the apical side was greatly reduced in small intestine of rab8 knockout mice (Fig 2) . 37) In the knockout mice, both PepT1 and Sglt1 are mislocalized in an intracellular compartment, presumably endosomes and/or lysosomes. 37) Such mislocalization and/or degradation in lysosomes presumably resulted in a marked reduction in the expression lev- Fig. 3 . Concept of multiplicity in relation to complexes of transporters, their adaptors, and other transporters commonly interacting with the adaptors. els of the transporters and in the absorption rate of nutrients in the small intestine.
Transfectant systems in mammalian cell lines (such as HEK293, HeLa, LLC-pK1, CHO, etc.) have been widely used to analyze the functions of xenobiotic transporters in vitro. In such systems, the roles of adaptor proteins have not yet been well established, but nevertheless, transporters are properly targeted to plasma membranes in most cases, and so are involved in the membrane permeation of substrates. It may be surprising that a single gene product (Pdzk1 or Rab8) is pivotal for the proper targeting of these transporters to plasma membranes in vivo, becauseˆndings in pdzk1 and rab8 knockout mice clearly demonstrated that cell-surface expression of certain transporters is strictly regulated by other proteins, including the PDZ adaptor. Most of the cell lines express at least some PDZ adaptors (PDZKs or NHERFs), 21) leading to the hypothesis that such endogenous adaptors are important for the targeting of exogenously transfected transporters.
PDZ adaptors: not just scaŠolds or regulators?
Several members of the G-protein-coupled receptor superfamily also have a PDZ binding motif at their Cterminus. Those include metabotropic glutamate receptor and GABA type-B receptor, both of which are expressed in the central nervous system. Protein-protein interaction via the PDZ binding motif could be involved in the formation of receptor complexes with their regulatory proteins, so-called signalosomes, leading to e‹cient signal transduction to downstream eŠectors. 38) Thus, PDZ adaptors may also play a role in signal transduction pathways, at least in the central nervous system.
Interactions with PDZK1, its homologue PDZK2, and NHERF1 may potentiate the function and/or expression of several xenobiotic transporters in vitro, and such interactions are established to occur in vivo, 14, [16] [17] [18] [19] 39) suggesting that these transporters function in the form of protein complexes. This raises a further question about the pharmacological signiˆcance of such complexes. The roles of xenobiotic transporters include the eOEux of many types of xenobiotic compounds from the body, and therefore, multispeciˆcity may be required in xenobiotic transport systems. It may be hypothesized that protein-protein interactions, at least in terms of protein-adaptor complexes, play a role in such multispeciˆcity (Fig. 3) . If we consider just transporters localized on the plasma membrane, the number of transport systems should be equal to the number of transporters. However, if we consider the transporteradaptor combinations, the number of transport systems is given by the product of the number of transporters and that of adaptors (Fig. 3) . In addition, the PDZdomain-containing adaptors may interact with more than one transporter, so the multiplicity of transport mechanisms may be further increased (Fig. 3) . A similar hypothesis has been put forward for the xenobioticmetabolizing enzyme UDP-glucuronosyltransferase Table 2 . Prospective targets of research on xenobiotic transporteradaptor networks 1. Application of transporter-adaptor complexes as more physiological screening systems for assessing membrane permeation of drugs and drug candidates 2. Discovery of novel transporters/adaptors involved in the networks 3. Evaluation of transporter-adaptor complexes as possible targets determining drug e‹cacy and/or toxicity 4. Evaluation of the rore of transporter-adaptor complexes in the multispeciˆcity of xenobiotic transport systems in the body 5. Examination of the feasibility of using adaptors or transporter/adaptor complexes as novel biomarkers (UGT): the interaction of heterologous UGTs aŠects the characteristics of the enzymatic activity. 40) A detailed analysis of the protein-protein interactions of xenobiotic transporters may reveal novel protein complexes involved in the membrane permeation of therapeutic agents.
PDZ domain-protein interactions have recently been recognized as a target for drug discovery. 24) Compared with the conventional approach toˆnding agonists/antagonists of a target protein, the discovery of drugs that can modulate the relevant protein-protein interactions may have several advantages, including (i) simultaneous eŠect on multiple proteins relevant to diseases, (ii) possibility of subunit selectivity and (iii) possibility of modifying particular protein pathways. 24) There remains a question as to whether the apparent function of a protein complex observed in vitro re‰ects the physiological function. The formation of networks may result in multispeciˆcity, but at the same time, it makes analysis di‹cult. However, physical interaction of transporter and adaptor in vivo is consistent with the idea that the function exerted by the complex may be more physiologically relevant than that by the transporter alone. Therefore, systematic analyses are needed to uncover the whole picture of xenobiotic transport systems, in order not only to understand the transport characteristics, but also to assist pharmacological and/or toxicological evaluation in the course of drug discovery and development.
Conclusion and prospects
We currently see only the tip of the iceberg in studies of the networks of transporters and other proteins, and a great deal of work will be needed to clarify the pharmacological signiˆcance of transporter-adaptor networks. Based on the present mini-review, we suggest that key targets of future research on xenobiotic transporters-adaptor complex may be as shown in Table 2 .
